In this protocol, we identified a novel population of melanocyte-like cells (also known as cardiac melanocytes) in the hearts of mice and humans that contribute to atrial arrhythmia triggers in mice.
Method Article
In this protocol, we identified a novel population of melanocyte-like cells (also known as cardiac melanocytes) in the hearts of mice and humans that contribute to atrial arrhythmia triggers in mice.
We identified a novel population of melanocyte-like cells (also known as cardiac melanocytes) in the hearts of mice and humans that contribute to atrial arrhythmia triggers in mice. To investigate the electrical and biological properties of cardiac melanocytes we developed a procedure to isolate them from mouse hearts that we derived from those designed to isolate neonatal murine cardiomyocytes. In order to obtain healthier cardiac melanocytes suitable for more extensive patch clamp or biochemical studies, we developed a refined procedure for isolating and plating cardiac melanocytes based on those originally designed to isolate cutaneous melanocytes. The refined procedure is demonstrated in this review and produces larger numbers of healthy melanocyte-like cells that can be plated as a pure population or with cardiomyocytes.
We recently identified a novel cell population in the heart of mice and humans that express melanin-synthesis enzymes and morphologically resemble cutaneous melanocytes. We called these cells 'cardiac melanocytes' and found they are present in anatomic locations from which atrial arrhythmia triggers often originate in humans. We also found cardiac melanocytes contribute to atrial arrhythmias in mice with germline deletion of Dct. Cardiac melanocytes are sparsely distributed throughout the mouse atrium where they comprise less than 0.1% of all atrial cells. To investigate the electrical and biological properties of cardiac melanocytes we developed a procedure to isolate them from the mouse heart using Cre-inducible melanocyte specific markers. Our initial procedure was developed from those used to isolate neonatal murine cardiomyocytes and yielded very small numbers of cells suitable for patch clamp recordings or PCR analysis. However, to improve the health and viability of cardiac melanocytes, for more in-depth electrophysiological analysis or biochemical studies, we developed a refined procedure from those designed to isolate cutaneous melanocytes. The procedure described and demonstrated in this review has the advantage of producing healthier cardiac melanocytes that can be plated as a pure population or with cardiomyocytes.
Access restricted. Please log in or start a trial to view this content.
1. Preparing the Necessary Solutions and Equipment
2. Isolating Hearts from Neonatal Mouse Pups
3. Enzymatic Digestion
4. Plating Cardiac Melanocyte-like Cells
5. Isolating Cardiac Melanocyte-like Cells from Adult Mouse Heart
Access restricted. Please log in or start a trial to view this content.
The protocol described in this article is an improved technique compared to the one we previously published for isolating cardiac melanocytes from the murine heart. This procedure employs the use of fluorescent markers driven by melanin synthesis enzyme-specific Cre-recombinase to label cardiac melanocyte-like cells. It is important to use a marker to label cardiac melanocytes when working with freshly isolated embryonic or neonatal cells, since the morphological differences that distinguish cardiac melanocytes from atri...
Access restricted. Please log in or start a trial to view this content.
Cardiac melanocytes are present in anatomic locations within the heart that commonly give rise to atrial arrhythmia triggers. These regions include the pulmonary veins, the atrioventricular annulus, the posterior left atrium and the foramen ovale (Figure 4). To understand the role these cells play in arrhythmogenesis, we develop techniques to isolate them and study their physiology. However, we recognized that improving this technique to yield healthier and larger quantities of cardiac melanocytes would ...
Access restricted. Please log in or start a trial to view this content.
We have nothing to disclose.
This work was supported by National Institutes of Health award R01 HL105734 to V.V.P. M.D.L. is supported, in part, by National Institutes of Health Research Career Award K08 HL094748. V.V.P. is an Innovative Researcher of the American Heart Association supported by grant 11IRG900384.
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| MCDB 153 | Sigma-Aldrich | M7403 | Dissolve in water |
| DPBS, no calcium no magnesium | Invitrogen | 14190136 | Stock conc.: 1x Working conc.: 1x |
| Penicillin-streptomycin | Invitrogen | 15140163 | Stock conc.: 100x Working conc.: 1x |
| Fetal Bovine Serum | Life Technology | Certified | Working conc.: 4% |
| TPA | Sigma-Aldrich | P1585 | Dissolve in DMSO Stock conc.: 3.2 μM Working conc.: 32 nM |
| Transferrin | Sigma-Aldrich | T8158 | Dissolve in DPBS Stock conc.: 0.1 mg/ml Working conc.: 1 μg/ml |
| Dibutyryl cyclic AMP | Sigma-Aldrich | D0627 | Dissolve in DPBS Stock conc.: 0.5 mM Working conc.: 5 μM |
| Insulin | Sigma-Aldrich | I6634 | Dissolve in 10 mM acetic acid Stock conc.: 1 mg/ml Working conc.: 5 μg/ml |
| Basic FGF | BD Biosciences | 354060 | Dissolve in water Stock conc.: 4 ng/μl Working conc.: 4 ng/ml |
Access restricted. Please log in or start a trial to view this content.
Request permission to reuse the text or figures of this JoVE article
Request Permission